US20220395460A1 - Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto - Google Patents

Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto Download PDF

Info

Publication number
US20220395460A1
US20220395460A1 US17/583,051 US202217583051A US2022395460A1 US 20220395460 A1 US20220395460 A1 US 20220395460A1 US 202217583051 A US202217583051 A US 202217583051A US 2022395460 A1 US2022395460 A1 US 2022395460A1
Authority
US
United States
Prior art keywords
inositol
pharmaceutical
nutraceutical composition
chiro
myo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/583,051
Inventor
Bernard FIORETTI
Lucio LEONARDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
S&R Farmaceutici SpA
Original Assignee
S&R Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56555565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20220395460(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S&R Farmaceutici SpA filed Critical S&R Farmaceutici SpA
Priority to US17/583,051 priority Critical patent/US20220395460A1/en
Assigned to S&R FARMACEUTICI S.P.A. reassignment S&R FARMACEUTICI S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FIORETTI, BERNARD, Leonardi, Lucio
Publication of US20220395460A1 publication Critical patent/US20220395460A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Definitions

  • FIG. 1 shows the effect on metabolism and proliferation of the oxidative stress and of the treatment with inositols and resveratrol. The measures have been performed in triplicate. Left (MTT) and (cell count).
  • the present invention relates to a pharmaceutical composition or nutraceutical composition or a supplementary food product for use a) in the preventative and/or curative treatment in metabolic disorders associated with polycystic ovary syndrome; b) in the treatment to reduce the symptoms associated with polycystic ovary syndrome such as menstrual cycle changes and infertility; and/or c) to decrease glucose, triglyceride and BMI levels in subjects with metabolic syndrome.
  • PCOS Polycystic ovary syndrome
  • PCOS is a complex syndrome: the anatomopathological picture consists of enlarged and micropolisic ovaries, while the clinical picture is characterized by metabolic disorders such as obesity, metabolic syndrome, dyslipidemia, hypertension, glucose intolerance, diabetes and endocrine disorders such as hyperandrogenism (acne, hirsutism, alopecia), menstrual cycle disorders, polycystic ovary, infertility.
  • metabolic disorders such as obesity, metabolic syndrome, dyslipidemia, hypertension, glucose intolerance, diabetes and endocrine disorders such as hyperandrogenism (acne, hirsutism, alopecia), menstrual cycle disorders, polycystic ovary, infertility.
  • PCOS diagnosis is based on the criteria proposed in 2003 by the Rotterdam ESHRE (European Society of Human Reproduction and Embryology), ASRM (American Society of Reproductive Medicine) PCOS Consensus Workshop Group that defines as PCOS the presence of at least two of the following criteria:
  • PCOS The etiopathogenesis of the PCOS is multifactorial. Hyperinsulinemia secondary to insulin resistance and the associated androgenic hypersecretion with decreased sex hormone-binding globulin (SHBG), constitute the central moment of PCOS pathogenesis. In addition, recently it has been observed that oxidative stress is involved in the pathogenesis of PCOS (1,2).
  • the compensatory hyperinsulinemia present in women with PCOS other than contributing significantly to the establishment of hormonal imbalance, results in an imbalance between free radicals and physiological antioxidant defenses of the body, triggering therefore oxidative stress (27).
  • oxidative stress is one of the causes that results in poor oocyte quality resulting in infertility or sub-fertility (5).
  • the therapeutic choices vary depending on the type and size of the patient's disorders, the priorities and the health expectations that the patient has at that time of his life and diverge drastically if the patient wants a pregnancy or not.
  • Two therapeutic strategies are distinguished: non-pharmacological ones, such as body weight reduction through an appropriate diet and a systematic program of aerobic exercise; and the pharmacological ones, which vary according to the desire or not of a pregnancy by the patients.
  • the therapeutic goal is to determine effective follicular stimulation and subsequent ovulation by clomiphene citrate, exogenous gonadotropins, pulsed GnRh; the risks associated with fertilization protocols are related to ovarian hyperstimulation.
  • the therapeutic goals are, on the one hand, the reduction of hyperandrogenism through oral contraceptives, anti-androgens, and GnRHs analogous (however, therapy is long-term—not less than 12 months—and signs may recur to the suspension of the treatment), on the other hand the insulin-resistance rebalancing via metformin and glitazones, insulin-sensitizing drugs.
  • Metformin and glitazones have currently the only authorized indication for type 2 diabetes mellitus in Italy, so their prescription in PCOS patients is “off-label”.
  • IPGs Inositol-phosphoglycans
  • GPI-L glycosyl-phosphatidyl-inositol
  • inositol performs its biological functions integrating into the phospholipids of the cell membrane.
  • Inositol is a vitamin factor that is part of the B complex naturally present in the human organism that stimulates and activates mitochondria, facilitating their breathing and activating all the processes of cell detoxification.
  • MI Myosin-inositol regulates calcium metabolism (8): MI regulates many cellular processes through the intracellular oscillation of Calcium (Ca2+), which acts on the cytoskeleton of the oocyte cell and is an important constituent of the follicular micro-environment. Studies carried out on the in vivo maturation of the oocytes and the effect of myo-inositol in improving it have suggested that there is a correlation between its concentration in the follicular fluid and the quality of the oocytes and embryo, improving spontaneous ovulation.
  • Ca2+ Calcium
  • DCI D-chiro inositol regulates glucose metabolism (9,10): DCI activates key enzymes that control oxidative and non-oxidative glucose metabolism. A defect on the release of the same contributes to the insulin resistance, whereas its administration boosts insulin action in PCOS patients by improving the severe metabolic abnormalities. In addition, the DCI is able to counteract oxidative stress (11) against proteins present in follicular fluid, which causes a reduced oocytic quality (12).
  • DCI D-chiro inositol
  • MI myo-inositol
  • studies on rats have shown that such synthesis and conversion occurs only to a small extent, while the amount present in the body mainly depends on the one absorbed with the diet.
  • insulin resistance has been associated with altered kidney excretion of chiro-inositol in primates, in humans with reduced glucose tolerance and with type 2 mellitus diabetes and in first-degree family members of diabetic patients with normal glucose tolerance (16-17, 19).
  • inositol administration reduces hyperglycemia in diabetic rats and improves glucose tolerance in normal rats (20).
  • Folic acid is a vitamin of the B group that is essential for nucleic acid synthesis, red blood cell production, and good nervous system status.
  • Folic acid reduces the levels of circulating homocysteine by converting it into methionine, resulting in improved ovulatory and insulin activity, thereby favoring fertility, correct ovulation maturation, and embryonic development processes.
  • the application WO 2013/076121 discloses a pharmaceutical composition comprising myo-inositol (MI) and D-chiro-inositol (DCI) in predetermined ratios (from 10:1 to 100:1) for the treatment of polycystic ovary syndrome (PCOS).
  • MI myo-inositol
  • DCI D-chiro-inositol
  • the composition described in this application also encompasses the association of said components with folic acid and other minor components.
  • Indian application IN1312MU2014 describes a pharmaceutical composition comprising MI and DCI in combination with vitamin D3 and other excipients for the treatment of PCOS.
  • resveratrol are also known for the treatment of menopause syndrome, as described for example in WO 2012107905, or for the treatment of PCOS as described for example in WO2006/013602.
  • WO 2006/013602 discloses a pharmaceutical or nutraceutical composition comprising omega-3 fatty acids, statins, coenzyme Q10, resveratrol, at least one policosanol, pantethin, selenium and zinc. It is believed that such combination has a synergistic effect and is useful in treating forms of diseases caused by insulin-resistance among which PCOS.
  • PCOS polycystic ovary syndrome
  • composition or formulation comprising at least one inositol and resveratrol co-precipitated with or supported on at least one hydroxide of a metal, preferably of a bivalent or trivalent metal, is able to meet the above-mentioned needs.
  • composition or formulation according to the invention is useful and effective in the
  • the Applicant surprisingly found that the association of at least one inositol (in particular a combination of myo-inositol (MI) and D-chiro-inositol (DCI) in predetermined ratios) with resveratrol co-precipitated with or supported on at least one hydroxide of a metal, preferably of hydroxides of a bivalent or trivalent metal, allows to obtain an improvement in the pathological state associated with PCOS, in particular a reduction of the oxidative stress, which is significantly higher than that obtainable from the treatment with the individual components of said association.
  • MI myo-inositol
  • DCI D-chiro-inositol
  • association of at least one inositol with resveratrol co-precipitated with or supported on at least one hydroxide of a metal, preferably of a bivalent or trivalent metal, has a synergistic effect on the treatment of PCOS and related pathological conditions, i.e. an effect that is significantly greater than the simple sum of the effects obtainable by treatments with the individual components of said association.
  • the metabolic syndrome is a clinical condition in which several related factors contribute to increase the possibility of developing pathologies due to the circulatory system and diabetes. Different metabolic abnormalities, such as central obesity, dyslipidaemia, insulin resistance, hypertension are distinguished (28).
  • the term “inositol” refers to inositol, or an inositol derivative, an inositol metabolite or an inositol analogue. It also includes any conformational isomer of the inositol which in particular: the scyllo, chiro, muco, neo-inositol, myo-inositol, allo-, epi- and cis-inositol and their combinations.
  • inositol examples include pinitol, e. g. D-pinitol or D-chiroinositol phosphate.
  • the composition according to the invention comprises a binary mixture of myo-inositol and d-chiro-inositol.
  • the composition according to the invention comprises a mixture of myo inositol and d-chiroinositol in a molar ratio [myo-inositol]/[d-chiro-inositol] comprised in a range from 0.01 to 100, preferably with a molar ratio between 1 and 5 and even more preferably less than 2.5 and even more preferably between 0.001 and 0.7 and even more preferably 0.4.
  • the MI/DCI ratio is less than or equal to the value found in healthy subjects (2.5) so that the relationship that characterizes the pathological state related to insulin resistance can be lowered.
  • the inositol or inositols content is within the range of 24% to 90% by weight on the weight of the composition.
  • resveratrol is present in the form of a co-precipitate with or supported on at least one hydroxide of a metal, preferably of a bivalent or trivalent metal.
  • Examples of preferred hydroxides include, without limitation, magnesium hydroxide, calcium hydroxide, zinc hydroxide, aluminum hydroxide, copper hydroxide, silver hydroxide and gold hydroxide.
  • the bivalent metal hydroxides are selected from the group consisting of magnesium hydroxide, calcium hydroxide and zinc hydroxide.
  • trivalent metal hydroxides are selected from aluminum hydroxide, chromium hydroxide and iron hydroxide.
  • resveratrol is a polyphenol with stylbenic structure contained in micromolar concentrations in red wine and in grape skin as well as in some plant species such as polyginum cuspidatum.
  • the resveratrol molecule has an optimal distribution coefficient to cross biological membranes, but being poorly soluble in water it is poorly absorbed.
  • the above formulation in which resveratrol is co-precipitated with at least one hydrocalcite or hydroxide permits to advantageously improve the dissolution rate of resveratrol after administering the composition of the invention to a subject in need and thereby increasing its bioavailability.
  • Formulations of this type are known in the art and preferably are used co-precipitated resveratrol formulations with hydrocalcitates and/or hydroxides as described in the patent application EP 2679243 whose content is here fully incorporated by reference.
  • a formulation containing trans-resveratrol supported on magnesium hydroxide is used.
  • the trans-resveratrol content in this formulation may be between 10% and 50% by weight on the weight of the formulation, preferably it is 30% by weight on the weight of the formulation.
  • Such a formulation is commercially sold under the trade name Revifast®. Revifast® has the following properties:
  • Revifast® is a microfine powder that, thanks to the presence of magnesium hydroxide, has high flowability (easy machinability) and good compressibility (in the case of tablet formulations) that make it easier to process the powder without the addition of additional excipients that improve its properties.
  • the resveratrol content resulting from a formulation supported on hydroxides in the composition according to the invention is in the range of 1% to 10% by weight on the weight of the composition.
  • composition according to the invention can be supplemented with agents that are recognized to show positive effects in the treatment of PCOS such as folic acid, lipoic acid, vitamin D and manganese.
  • the folic acid content is within the range from 0.001% to 0.1% by weight on the weight of the composition.
  • the manganese content is in the range from 0.001% to 5% by weight on the weight of the composition.
  • Manganese (Mn) is an essential trace element. Trace elements are substances that, although present in our body at small concentration, play an indispensable role to ensure the individual's psycho-physical well-being.
  • manganese The biological role of manganese is now widely recognized by the scientific community. It actively participates in many biological mechanisms: coagulation, thyroid function, fertility (regulates the production of sex hormones), it contrasts hyperglycemia, contributes to maintain the skeletal system in good health. During pregnancy, in particular, it is indispensable for a physiological fetal development.
  • manganese is cofactor of numerous enzymes such as superoxide dismutase (SOD) (27), the primary preventive antioxidant essential to counter oxidative stress.
  • SOD superoxide dismutase
  • the latter also appears to have a pathogenic role in male and female infertility/sub-fertility states. It is involved in the synthesis of DNA and RNA and regulates glucogenesis.
  • the alpha-lipoic acid content is in the range of 0.1% to 10% by weight on the weight of the composition.
  • the vitamin D content is comprised within the range from 0.00015 to 0.1% by weight on the weight of the composition.
  • vitamin D is vitamin D3.
  • composition according to the invention may further comprise excipients, technological additives, co-formulants, polar and semipolar polymer matrices, vectors and stabilizers both for pharmaceutical and nutritional use commonly used in the pharmaceutical industry and known to those skilled in the art.
  • excipients are gums of xanthan and guar gum, sweetening such as glucose and sucrose, acidifying such as citric acid and sliding agents such as stearic acid, anti-agglomerating agents such as vegetable magnesium stearate and silicon dioxide and filler agents such as microcrystalline cellulose, arabic gum, crosslinked sodium carboxymethylcellulose.
  • the weight percentage of the optional excipients may be between 0 and 50%, preferably between 10 and 20%.
  • composition according to the invention can be prepared in various ways in pharmaceutical form, nutraceutical form or as a dietary food supplement according to methods per se known to the skilled in the art.
  • Such preparations include:
  • solid preparations for oral and buccal use powders, granules, granules, capsules, pills, chewing gums, bolus, cachets, tablets, lozenges, medicinal chocolates;
  • liquid/semisolid preparation for oral use syrups, elixirs, pastes, juices, decoction, suspensions, emulsions, mucilages, herbal teas, medicinal wines, and potions;
  • preparations for skin applications creams, ointments, gels, emulsions, lotions, linings, medicinal soaps, medicinal or non-medical shampoos, skin pencils, poultice, gums, oils, oleolites, ointments, dyes, medicated gauzes;
  • ear, nasal and mucous membrane preparations collutories, gargles, ear washings, ear cuffs, nasal washings, tampons, oils, oleolites, emulsions, ointments, gels, emulgel, lipogels, tablets, capsules, films, medicated plasters;
  • ophthalmic preparations eye drops, ophthalmic inserts and ocular baths
  • preparations administered through the lower (anal and vaginal) cavities suppositories, capsules, tablets, enemas, medical irrigation, lavages, foams, tampons, pessary, ovule drugs, foams, gels, pastes, emulsions, creams, ointments, films, suspensions, wraps, plaster, rings, tampons, medicated gauzes;
  • composition according to the invention may be administered in doses from 200 mg to 1000 mg and preferably 805 mg.
  • folic acid is supplemented so as to provide daily amounts of between 100 micrograms and 1 mg, more preferably between 100 and 500 micro grams, and more preferably between 200 and 400 micrograms.
  • the manganese is supplemented in the form of salts such as gluconate, pidolate, chloride to make a daily amount of Mn between 1 mg and 50 mg, more preferably between 5 and 10 mg.
  • salts such as gluconate, pidolate, chloride to make a daily amount of Mn between 1 mg and 50 mg, more preferably between 5 and 10 mg.
  • composition according to the invention An exemplary formulation of the composition according to the invention is described below:
  • Example 1 The composition described in Example 1 can be contained in a variety of formulations such as capsules, tablets, lotions, patches, etc.
  • Example 1 can be supplemented with agents that are recognized to show positive effects in the treatment of PCOS such as folic acid, vitamin D and manganese.
  • composition according to the invention is as follows:
  • the formulations of Examples 1 and 2 also include various excipients, technological additives, co-formulants, polar and semipolar polymer matrices, carriers and stabilizers for both pharmaceutical and nutraceutical purposes.
  • excipients are xanthan gum and guar gum, sweetening such as glucose and sucrose, acidifying such as citric acid, sliding agents such as stearic acid, anti-agglomerating agents such as vegetable magnesium stearate and silicon dioxide and filler agents such as microcrystalline cellulose, arabic gum, crosslinked sodium carboxymethylcellulose.
  • the weight percentage of any excipients may be between 0 and 50%, preferably between 10 and 20%.
  • Example 2 The composition described in Example 2 can be contained in a variety of formulations such as capsules, tablets, lotions, patches, etc.
  • formulations of which the formulations 1 and 2 are an example may be administered in a daily dosage regimen in two or more moments, preferably in two daily doses.
  • FBS fetal bovine serum
  • the effects of treatments on cellular metabolism were evaluated by the MTT test, while on the proliferation by cell count in Burker's chamber and all effects were compared with growing cells under controlled conditions (DMEN+10% FBS).
  • Ms. AC is affected by PCOS and in her diet integration scheme she has taken both supplements with a myo-inositol/D chiro-inositol ratio of 0.4 and Revifast® resveratrol supplements separately. Although she has shown improvements in the symptomatic framework, she has not had an improvement such as to allow to have for example the possibility of a pregnancy. Occasionally Ms. AC took these two supplements at one time and had a synergistic improvement of the pathology with the onset of a pregnancy as shown by the ultrasound picture ( FIG. 1 ). The quantities taken by Ms. AC are such that the posology used is that shown in Example 1 or 2.
  • Mr. LL has a blood glucose level of 123 mg/dL, a body mass index (BMI) of 31, systemic pressure 130/90 mmHg and a triglycerides value of 150 mg/dL, such parameters indicating the presence of a metabolic syndrome.
  • BMI body mass index
  • triglycerides value 150 mg/dL, such parameters indicating the presence of a metabolic syndrome.
  • the subject took separately as food supplementation scheme both supplements with a myo-inositol/D-chiro inositol ratio of 0.4 and Revifast® resveratrol supplements. Though he showed improvements in the symptomatic framework, he did not have a significant reduction in body weight. Occasionally Mr.
  • LL took these two supplements simultaneously and had a significant reduction in blood glucose (115 mg/dl) and of the Homa index indicating an improvement in insulin resistance. In addition, there was a reduction in triglyceride levels (135 mg/dl) and systemic pressure 125/85 mmHg and of the weight with a BMI index of 27. The amounts taken by Mr. LL are such that the posology used is that reported in Example 1 and 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical or nutraceutical composition having at least one inositol and resveratrol for use in a) preventive and/or curative treatment in metabolic disorders related to polycystic ovary syndrome; b) treatment to reduce symptoms associated with polycystic ovary syndrome such as menstrual cycle alterations and infertility; and/or c) to decrease glucose, triglyceride and BMI levels in subjects with metabolic syndrome.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application is a continuation of U.S. application Ser. No. 16/093,295 filed on Oct. 12, 2018, which, in turn, is the US national stage of International Patent Application PCT/IB2017/052151 filed on Apr. 13, 2017, the entire disclosure of all of which is hereby incorporated by reference herein. International Patent Application PCT/IB2017/052151 filed on Apr. 13, 2017 in turn, claims priority to Italian application 102016000038243 filed on Apr. 13, 2016.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the effect on metabolism and proliferation of the oxidative stress and of the treatment with inositols and resveratrol. The measures have been performed in triplicate. Left (MTT) and (cell count).
    • DESCRIPTION Field of Application
  • The present invention relates to a pharmaceutical composition or nutraceutical composition or a supplementary food product for use a) in the preventative and/or curative treatment in metabolic disorders associated with polycystic ovary syndrome; b) in the treatment to reduce the symptoms associated with polycystic ovary syndrome such as menstrual cycle changes and infertility; and/or c) to decrease glucose, triglyceride and BMI levels in subjects with metabolic syndrome.
    • Known Art
  • Polycystic ovary syndrome (PCOS) is one of the most common hormonal disorders in women, being present in 5-10% of women of childbearing age (1) and being also the most common cause of female infertility related to the absence of ovulation (called anovulatory infertility).
  • PCOS is a complex syndrome: the anatomopathological picture consists of enlarged and micropolisic ovaries, while the clinical picture is characterized by metabolic disorders such as obesity, metabolic syndrome, dyslipidemia, hypertension, glucose intolerance, diabetes and endocrine disorders such as hyperandrogenism (acne, hirsutism, alopecia), menstrual cycle disorders, polycystic ovary, infertility.
  • The PCOS diagnosis is based on the criteria proposed in 2003 by the Rotterdam ESHRE (European Society of Human Reproduction and Embryology), ASRM (American Society of Reproductive Medicine) PCOS Consensus Workshop Group that defines as PCOS the presence of at least two of the following criteria:
      • oligomenorrhoea and/or anovulation;
      • clinical and/or biochemical signs of hyperandrogenism;
      • polycystic ecostructure of the ovary;
      • in the absence of congenital adrenal hyperplasia, Cushing's syndrome, and adrenal or ovarian secretion-specific androgenic tumors (2).
  • The etiopathogenesis of the PCOS is multifactorial. Hyperinsulinemia secondary to insulin resistance and the associated androgenic hypersecretion with decreased sex hormone-binding globulin (SHBG), constitute the central moment of PCOS pathogenesis. In addition, recently it has been observed that oxidative stress is involved in the pathogenesis of PCOS (1,2).
  • The compensatory hyperinsulinemia present in women with PCOS, other than contributing significantly to the establishment of hormonal imbalance, results in an imbalance between free radicals and physiological antioxidant defenses of the body, triggering therefore oxidative stress (27).
  • The latter plays a decisive role in pathogenesis and complications following polycystic ovary syndrome. In fact, it is believed that oxidative stress is one of the causes that results in poor oocyte quality resulting in infertility or sub-fertility (5).
  • The therapeutic choices vary depending on the type and size of the patient's disorders, the priorities and the health expectations that the patient has at that time of his life and diverge drastically if the patient wants a pregnancy or not.
  • Two therapeutic strategies are distinguished: non-pharmacological ones, such as body weight reduction through an appropriate diet and a systematic program of aerobic exercise; and the pharmacological ones, which vary according to the desire or not of a pregnancy by the patients.
  • In the first case, the therapeutic goal is to determine effective follicular stimulation and subsequent ovulation by clomiphene citrate, exogenous gonadotropins, pulsed GnRh; the risks associated with fertilization protocols are related to ovarian hyperstimulation.
  • In the second case, the therapeutic goals are, on the one hand, the reduction of hyperandrogenism through oral contraceptives, anti-androgens, and GnRHs analogous (however, therapy is long-term—not less than 12 months—and signs may recur to the suspension of the treatment), on the other hand the insulin-resistance rebalancing via metformin and glitazones, insulin-sensitizing drugs. Metformin and glitazones have currently the only authorized indication for type 2 diabetes mellitus in Italy, so their prescription in PCOS patients is “off-label”.
  • The hypothesis of a defect in the signal transduction of insulin due to the lack of second messengers (6.7) and the recognition of the important pathophysiological role of insulin resistance and consequent hyperinsulinaemia and oxidative stress in PCOS, have provided the rationale for the introduction into the treatment of these patients of the inositolphosphoglycans.
  • Inositol-phosphoglycans (IPGs) are the non-classical insulin signal cascade mediators for the absorption of glucose and its use. Some insulin actions may involve the inositolphosphoglycans mediators: when insulin binds to its receptor, the mediators of this class are generated by the lipid hydrolysis of glycosyl-phosphatidyl-inositol (GPI-L) located on the cytoplasmatic sheet of the cell membrane.
  • Thus, inositol performs its biological functions integrating into the phospholipids of the cell membrane.
  • Inositol is a vitamin factor that is part of the B complex naturally present in the human organism that stimulates and activates mitochondria, facilitating their breathing and activating all the processes of cell detoxification.
  • It exists in nine possible stereoisomers, whose widely resembling form is cis-1,2,3,5-trans-4,6-cyclohexanenesol, or myo-inositol (ancient name meso-inositol). Other isomers present in nature are the scyllo-, chiro-, muco-, neo-inositol and possible isomers are also allo-, epi- and cis-inositol.
  • Myosin-inositol (MI) regulates calcium metabolism (8): MI regulates many cellular processes through the intracellular oscillation of Calcium (Ca2+), which acts on the cytoskeleton of the oocyte cell and is an important constituent of the follicular micro-environment. Studies carried out on the in vivo maturation of the oocytes and the effect of myo-inositol in improving it have suggested that there is a correlation between its concentration in the follicular fluid and the quality of the oocytes and embryo, improving spontaneous ovulation.
  • D-chiro inositol (DCI) regulates glucose metabolism (9,10): DCI activates key enzymes that control oxidative and non-oxidative glucose metabolism. A defect on the release of the same contributes to the insulin resistance, whereas its administration boosts insulin action in PCOS patients by improving the severe metabolic abnormalities. In addition, the DCI is able to counteract oxidative stress (11) against proteins present in follicular fluid, which causes a reduced oocytic quality (12). D-chiro inositol (DCI) is synthesized and converted from myo-inositol (MI) through the enzyme epimerase; however, studies on rats have shown that such synthesis and conversion occurs only to a small extent, while the amount present in the body mainly depends on the one absorbed with the diet.
  • The MI/DCI ratio measured in several districts, for example in the urine, is directly related to insulin resistance (13, 14): the MI/DCI ratio in physiological conditions is around 2.5 while increases in the presence of particular conditions characterized by Insulin resistance, such as:
      • type II diabetes
      • first-degree familiarity for type II diabetes
      • type I diabetes
  • TABLE 1
    Values of the myo-inositol/D-chiro inositol ratio in diabetic,
    control and predisposed subjects (16).
    Subjects (MI/DCI) Ratio
    Healthy controls 2.5
    Type II diabetic patients 20.4
    Type II diabetic patients—first degree 13.2
    Type I diabetic patients 13.6
  • In fact, it has been observed that under insulin resistance conditions there is a chiro-inositol deficiency in the muscle of subjects with type 2 mellitus diabetes compared to normal subjects and experimental animals (15,16,17,18).
  • Finally, insulin resistance has been associated with altered kidney excretion of chiro-inositol in primates, in humans with reduced glucose tolerance and with type 2 mellitus diabetes and in first-degree family members of diabetic patients with normal glucose tolerance (16-17, 19).
  • In experimental models, inositol administration reduces hyperglycemia in diabetic rats and improves glucose tolerance in normal rats (20).
  • Also in other pathological states characterized by insulin resistance, such as PCOS, an increase of the MI/DCI ratio is observed (21): this is because patients with PCOS exhibit a defect in DCI release and a reduced activity of the epimerase enzyme (22).
  • Folic acid is a vitamin of the B group that is essential for nucleic acid synthesis, red blood cell production, and good nervous system status.
  • Folic acid reduces the levels of circulating homocysteine by converting it into methionine, resulting in improved ovulatory and insulin activity, thereby favoring fertility, correct ovulation maturation, and embryonic development processes.
  • Most women with PCOS have insulin-resistance associated with high levels of homocysteine that cause an increase in oxidative stress in the vascular endothelium, associated with platelet activation and stimulation of the vascular smooth muscle proliferation. Thus, this metabolite, interfering with endometrial blood flow and vascular integrity, could favor spontaneous abortion and complications during pregnancy in women who were already unproductive because of the above-mentioned syndrome.
  • The application WO 2013/076121 discloses a pharmaceutical composition comprising myo-inositol (MI) and D-chiro-inositol (DCI) in predetermined ratios (from 10:1 to 100:1) for the treatment of polycystic ovary syndrome (PCOS). The composition described in this application also encompasses the association of said components with folic acid and other minor components.
  • Indian application IN1312MU2014 describes a pharmaceutical composition comprising MI and DCI in combination with vitamin D3 and other excipients for the treatment of PCOS.
  • Pharmaceutical formulations containing resveratrol are also known for the treatment of menopause syndrome, as described for example in WO 2012107905, or for the treatment of PCOS as described for example in WO2006/013602. In particular, WO 2006/013602 discloses a pharmaceutical or nutraceutical composition comprising omega-3 fatty acids, statins, coenzyme Q10, resveratrol, at least one policosanol, pantethin, selenium and zinc. It is believed that such combination has a synergistic effect and is useful in treating forms of diseases caused by insulin-resistance among which PCOS.
  • Furthermore, in animal models (rats) with PCOS induced by hormone stimulation, resveratrol treatment has been shown to regularize the menstrual cycle and improve the edipositis but does not improve the resistance-insulin picture that is observed with physical activity (23).
  • The search for PCOS treatments is currently still insufficient and the search for a safe formulation that is effective in resolving the syndrome is still absent.
  • Therefore the need remains to provide a new formulation that is effective in treating or at least reducing metabolic disorders associated with polycystic ovary syndrome (PCOS) and/or the symptoms associated with PCOS.
  • There is also the need to provide a new formulation that is effective in lowering glucose, triglyceride and/or BMI levels in subjects with metabolic syndrome.
  • In particular, there remains a need to provide a novel and effective formulation for the above treatments which can be well tolerated by the treated subjects without significant side effects and which is easy to administer.
    • SUMMARY OF THE INVENTION
  • The Applicant has now found that a composition or formulation comprising at least one inositol and resveratrol co-precipitated with or supported on at least one hydroxide of a metal, preferably of a bivalent or trivalent metal, is able to meet the above-mentioned needs.
  • In particular, the composition or formulation according to the invention is useful and effective in the
  • a) preventive and/or curative treatment in the metabolic disorders related to polycystic ovary syndrome;
  • b) treatment to reduce the symptoms associated with polycystic ovary syndrome such as menstrual cycle alterations and infertility; and/or
  • c) to decrease glucose, triglyceride and BMI levels in subjects with metabolic syndrome.
  • Indeed, as shown in the experimental part reported below, the Applicant surprisingly found that the association of at least one inositol (in particular a combination of myo-inositol (MI) and D-chiro-inositol (DCI) in predetermined ratios) with resveratrol co-precipitated with or supported on at least one hydroxide of a metal, preferably of hydroxides of a bivalent or trivalent metal, allows to obtain an improvement in the pathological state associated with PCOS, in particular a reduction of the oxidative stress, which is significantly higher than that obtainable from the treatment with the individual components of said association. In other words, the association of at least one inositol with resveratrol co-precipitated with or supported on at least one hydroxide of a metal, preferably of a bivalent or trivalent metal, has a synergistic effect on the treatment of PCOS and related pathological conditions, i.e. an effect that is significantly greater than the simple sum of the effects obtainable by treatments with the individual components of said association.
  • Similar results are also obtained in the reduction of glucose, triglyceride and BMI levels in subjects with metabolic syndrome.
  • The metabolic syndrome is a clinical condition in which several related factors contribute to increase the possibility of developing pathologies due to the circulatory system and diabetes. Different metabolic abnormalities, such as central obesity, dyslipidaemia, insulin resistance, hypertension are distinguished (28).
  • In the composition according to the invention, the term “inositol” refers to inositol, or an inositol derivative, an inositol metabolite or an inositol analogue. It also includes any conformational isomer of the inositol which in particular: the scyllo, chiro, muco, neo-inositol, myo-inositol, allo-, epi- and cis-inositol and their combinations.
  • Examples of derivatives and analogs of the inositol are, for example, pinitol, e. g. D-pinitol or D-chiroinositol phosphate.
  • Preferably, the composition according to the invention comprises a binary mixture of myo-inositol and d-chiro-inositol.
  • In particular, according to a preferred embodiment of the invention, the composition according to the invention comprises a mixture of myo inositol and d-chiroinositol in a molar ratio [myo-inositol]/[d-chiro-inositol] comprised in a range from 0.01 to 100, preferably with a molar ratio between 1 and 5 and even more preferably less than 2.5 and even more preferably between 0.001 and 0.7 and even more preferably 0.4.
  • Advantageously, according to one aspect of the present invention, the MI/DCI ratio is less than or equal to the value found in healthy subjects (2.5) so that the relationship that characterizes the pathological state related to insulin resistance can be lowered.
  • Preferably, in the composition according to the invention, the inositol or inositols content is within the range of 24% to 90% by weight on the weight of the composition.
  • In the composition according to the invention, resveratrol is present in the form of a co-precipitate with or supported on at least one hydroxide of a metal, preferably of a bivalent or trivalent metal.
  • Examples of preferred hydroxides include, without limitation, magnesium hydroxide, calcium hydroxide, zinc hydroxide, aluminum hydroxide, copper hydroxide, silver hydroxide and gold hydroxide.
  • Preferably, the bivalent metal hydroxides are selected from the group consisting of magnesium hydroxide, calcium hydroxide and zinc hydroxide.
  • Preferably, trivalent metal hydroxides are selected from aluminum hydroxide, chromium hydroxide and iron hydroxide.
  • In fact, resveratrol is a polyphenol with stylbenic structure contained in micromolar concentrations in red wine and in grape skin as well as in some plant species such as polyginum cuspidatum. The resveratrol molecule has an optimal distribution coefficient to cross biological membranes, but being poorly soluble in water it is poorly absorbed. Conversely, the above formulation in which resveratrol is co-precipitated with at least one hydrocalcite or hydroxide permits to advantageously improve the dissolution rate of resveratrol after administering the composition of the invention to a subject in need and thereby increasing its bioavailability.
  • Formulations of this type are known in the art and preferably are used co-precipitated resveratrol formulations with hydrocalcitates and/or hydroxides as described in the patent application EP 2679243 whose content is here fully incorporated by reference.
  • According to a particularly preferred embodiment, in the composition according to the invention a formulation containing trans-resveratrol supported on magnesium hydroxide is used. The trans-resveratrol content in this formulation may be between 10% and 50% by weight on the weight of the formulation, preferably it is 30% by weight on the weight of the formulation. Such a formulation is commercially sold under the trade name Revifast®. Revifast® has the following properties:
      • the resveratrol contained therein has an increased rate of dissolution at the pH of the gastric environment compared to the resveratrol tout court (Polygonum Cuspidatum, 98%),
      • due to the increased rate of dissolution of resveratrol so formulated, it is conceivable its higher expected bioavailability based on its high membrane permeability,
      • the improved dissolution rate and the consequent increase in the amount of resveratol absorbed in the time unit creates a gradient between re sveratrol still in solid state and the gastric environment which promotes the continuous passage into solution of the solid until it is fully dissolved;
      • the best dissolution rate is expected to increase its pharmacokinetic properties such as the maximal plasmatic peak and generally its oral bioavailability.
  • It should be noted further that Revifast® is a microfine powder that, thanks to the presence of magnesium hydroxide, has high flowability (easy machinability) and good compressibility (in the case of tablet formulations) that make it easier to process the powder without the addition of additional excipients that improve its properties.
  • Preferably, the resveratrol content resulting from a formulation supported on hydroxides in the composition according to the invention is in the range of 1% to 10% by weight on the weight of the composition.
  • The composition according to the invention can be supplemented with agents that are recognized to show positive effects in the treatment of PCOS such as folic acid, lipoic acid, vitamin D and manganese.
  • Preferably, in the composition according to the invention, the folic acid content is within the range from 0.001% to 0.1% by weight on the weight of the composition.
  • Preferably, in the composition according to the invention, the manganese content is in the range from 0.001% to 5% by weight on the weight of the composition.
  • Manganese (Mn) is an essential trace element. Trace elements are substances that, although present in our body at small concentration, play an indispensable role to ensure the individual's psycho-physical well-being.
  • The biological role of manganese is now widely recognized by the scientific community. It actively participates in many biological mechanisms: coagulation, thyroid function, fertility (regulates the production of sex hormones), it contrasts hyperglycemia, contributes to maintain the skeletal system in good health. During pregnancy, in particular, it is indispensable for a physiological fetal development.
  • From a biochemical point of view, manganese is cofactor of numerous enzymes such as superoxide dismutase (SOD) (27), the primary preventive antioxidant essential to counter oxidative stress. The latter also appears to have a pathogenic role in male and female infertility/sub-fertility states. It is involved in the synthesis of DNA and RNA and regulates glucogenesis.
  • In addition, it plays an important synergistic activity with D-chiro-inositol, implementing the use of glucose by mitochondria; in the present invention it has been found that the association of Mn to the at least one inositol and to resveratrol contributes to reducing insulin resistance and, through a synergistic activity with DCI, to improve the metabolic syndrome associated to PCOS.
  • Preferably, in the composition according to the invention, the alpha-lipoic acid content is in the range of 0.1% to 10% by weight on the weight of the composition.
  • Preferably, in the composition according to the invention, the vitamin D content is comprised within the range from 0.00015 to 0.1% by weight on the weight of the composition.
  • Preferably, vitamin D is vitamin D3.
  • The composition according to the invention may further comprise excipients, technological additives, co-formulants, polar and semipolar polymer matrices, vectors and stabilizers both for pharmaceutical and nutritional use commonly used in the pharmaceutical industry and known to those skilled in the art. Examples of excipients are gums of xanthan and guar gum, sweetening such as glucose and sucrose, acidifying such as citric acid and sliding agents such as stearic acid, anti-agglomerating agents such as vegetable magnesium stearate and silicon dioxide and filler agents such as microcrystalline cellulose, arabic gum, crosslinked sodium carboxymethylcellulose. The weight percentage of the optional excipients may be between 0 and 50%, preferably between 10 and 20%.
  • The composition according to the invention can be prepared in various ways in pharmaceutical form, nutraceutical form or as a dietary food supplement according to methods per se known to the skilled in the art. Such preparations include:
  • a) solid preparations for oral and buccal use: powders, granules, granules, capsules, pills, chewing gums, bolus, cachets, tablets, lozenges, medicinal chocolates;
  • b) liquid/semisolid preparation for oral use: syrups, elixirs, pastes, juices, decoction, suspensions, emulsions, mucilages, herbal teas, medicinal wines, and potions;
  • c) preparations for skin applications: creams, ointments, gels, emulsions, lotions, linings, medicinal soaps, medicinal or non-medical shampoos, skin pencils, poultice, gums, oils, oleolites, ointments, dyes, medicated gauzes;
  • d) ear, nasal and mucous membrane preparations: collutories, gargles, ear washings, ear cuffs, nasal washings, tampons, oils, oleolites, emulsions, ointments, gels, emulgel, lipogels, tablets, capsules, films, medicated plasters;
  • e) ophthalmic preparations (eye drops, ophthalmic inserts and ocular baths);
  • f) preparations administered through the lower (anal and vaginal) cavities: suppositories, capsules, tablets, enemas, medical irrigation, lavages, foams, tampons, pessary, ovule drugs, foams, gels, pastes, emulsions, creams, ointments, films, suspensions, wraps, plaster, rings, tampons, medicated gauzes;
  • g) spray preparations for topical, inhalation, oral, buccal use.
  • The composition according to the invention may be administered in doses from 200 mg to 1000 mg and preferably 805 mg.
  • Preferably, folic acid is supplemented so as to provide daily amounts of between 100 micrograms and 1 mg, more preferably between 100 and 500 micro grams, and more preferably between 200 and 400 micrograms.
  • Preferably, the manganese is supplemented in the form of salts such as gluconate, pidolate, chloride to make a daily amount of Mn between 1 mg and 50 mg, more preferably between 5 and 10 mg.
  • Further features and advantages of the present invention will become apparent from the following description of some preferred embodiment examples for indicative and non-limiting purposes.
    • Example 1
  • An exemplary formulation of the composition according to the invention is described below:
  • w/w percentage of the
    Component Dose component on the formula
    myo-inositol 200 mg 25.6%
    d-chiro-inositol 500 mg 64.1%
    Revifast ® 150 mg 10.3% of which
    3.1% of resveratrol and 7.2%
    of magnesium hydroxide
  • The composition described in Example 1 can be contained in a variety of formulations such as capsules, tablets, lotions, patches, etc.
  • The formulation of Example 1 can be supplemented with agents that are recognized to show positive effects in the treatment of PCOS such as folic acid, vitamin D and manganese.
    • Example 2
  • Another exemplificative formulation of the composition according to the invention is as follows:
  • w/w percentage of the
    Component Dose component on the formula
    myo-inositol  200 mg 24.8%
    d-chiro-inositol  500 mg 62.0%
    Revifast ®   80 mg 10.0% of which 3.0% of
    resveratrol (24 mg) and 7% of
    magnesium hydroxide (56 mg)
    Folic acid  200 micrograms 0.024
    Mn pidolate   25 mg 3.1% of which 0.6% Mn (5 mg)
    and 2.5% of pidolate (20 mg)
    Vitamin D3 12.5 micrograms 0.0015%
    (cholecalciferol)
  • The formulations of Examples 1 and 2 also include various excipients, technological additives, co-formulants, polar and semipolar polymer matrices, carriers and stabilizers for both pharmaceutical and nutraceutical purposes. Examples of excipients are xanthan gum and guar gum, sweetening such as glucose and sucrose, acidifying such as citric acid, sliding agents such as stearic acid, anti-agglomerating agents such as vegetable magnesium stearate and silicon dioxide and filler agents such as microcrystalline cellulose, arabic gum, crosslinked sodium carboxymethylcellulose. The weight percentage of any excipients may be between 0 and 50%, preferably between 10 and 20%.
  • The composition described in Example 2 can be contained in a variety of formulations such as capsules, tablets, lotions, patches, etc.
  • The formulations of which the formulations 1 and 2 are an example may be administered in a daily dosage regimen in two or more moments, preferably in two daily doses.
    • Example 3.—In Vitro Experiment
  • Human embryonic kidney HEK293 cells were grown in adherence in a growth medium consisting of DMEM supplemented with 10% fetal bovine serum (FBS) for 24 hours before being treated with 300 μM hydrogen peroxide in the presence of inositols (MI-D-chirol, 40 μM myoinositol and 100 μM D-chiro inositol, molar ratio MUD-ChiroI=0.4) or resveratrol (10 μM) or in a combination of inositol and resveratrol. The effects of treatments on cellular metabolism were evaluated by the MTT test, while on the proliferation by cell count in Burker's chamber and all effects were compared with growing cells under controlled conditions (DMEN+10% FBS). The inositol concentrations were chosen based on the myo-inositol (MI) plasma concentration (26), and considering the molar ratio MI/D-ChiroI=0.4 according to the invention, while the resveratrol concentration (10 μM) was chosen considering the plasma concentration expected after a treatment regime with resveratrol supported on hydroxide such as that from Revifast. As it can be seen both metabolic activity (left panel) and cell number (right panel) are consistent in showing a anti-proliferative effect promoted by oxidative stress induced by hydrogen peroxide and how this effect is completely preserved by the combined treatment with inositol and resveratrol. In contrast, the inhibitory effect of oxidative stress is not modified by treatment with inositols, whereas this effect is only partially counteracted by resveratrol, in a statistically degree inferior to combined treatment thereby detecting the synergy between inositols and resveratrol in counteracting oxidative cellular stress. Oxidative stress aggravates the pathological state of PCOS along with hormonal imbalance (27).
    • Example 4.—In Vivo Experiment
  • Ms. AC is affected by PCOS and in her diet integration scheme she has taken both supplements with a myo-inositol/D chiro-inositol ratio of 0.4 and Revifast® resveratrol supplements separately. Although she has shown improvements in the symptomatic framework, she has not had an improvement such as to allow to have for example the possibility of a pregnancy. Occasionally Ms. AC took these two supplements at one time and had a synergistic improvement of the pathology with the onset of a pregnancy as shown by the ultrasound picture (FIG. 1 ). The quantities taken by Ms. AC are such that the posology used is that shown in Example 1 or 2.
    • Example 5.—In Vivo Experiment
  • Mr. LL has a blood glucose level of 123 mg/dL, a body mass index (BMI) of 31, systemic pressure 130/90 mmHg and a triglycerides value of 150 mg/dL, such parameters indicating the presence of a metabolic syndrome. For a predetermined period of treatment, the subject took separately as food supplementation scheme both supplements with a myo-inositol/D-chiro inositol ratio of 0.4 and Revifast® resveratrol supplements. Though he showed improvements in the symptomatic framework, he did not have a significant reduction in body weight. Occasionally Mr. LL took these two supplements simultaneously and had a significant reduction in blood glucose (115 mg/dl) and of the Homa index indicating an improvement in insulin resistance. In addition, there was a reduction in triglyceride levels (135 mg/dl) and systemic pressure 125/85 mmHg and of the weight with a BMI index of 27. The amounts taken by Mr. LL are such that the posology used is that reported in Example 1 and 2.
    • LIST OF REFERENCES
    • (1) Ehrmann D A. Polycystic ovary syndrome. N Engl J Med 2005
    • (2) Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004
    • (3) Zoe E C Hopkinson et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ 1998
    • (4) Pinar H. et al Statins: Do they have potential in the treatment of polycystic ovary syndrome? Semin Reprod Med. 2008
    • (5) Agarwal A. et al Oxidative stress and its implications in female infertility—a clinician's perspective. Reprod Biomed Online. 2005
    • (6) Lamer et al. D-Chiro-Inositol Glycans in Insulin Signaling and Insulin Resistance. Mol Med 2010
    • (7) Lamer et al. D-Chiro-Inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002
    • (8) Chiu, Rogers et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum. Reprod. 2002
    • (9) Lamer et al. D-Chiro-Inositol Glycans in Insulin Signaling and Insulin Resistance. Mol Med 2010
    • (10) Lamer et al. D-Chiro-Inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002
    • (11) V. De Leo et al. Valutazione del trattamento con D-Chiro-Inositolo sui livelli di stress ossidativo nelle pazienti con PCOS. Minerva Ginecologica 2012
    • (12) Agarwal A. et al. Oxidative stress and its implications in female infertility—a clinican's perspective. Reprod Biomed Online. 2005
    • (13) Lamer et al. D-Chiro-Inositol Glycans in Insulin Signaling and Insulin Resistance. Mol Med 2010
    • (14) Tae-Sik Jung et al. Determination of Urinary Myo-/Chiro-Inositol Ratios from Korean Diabetes Patients. Yonsei Medical Journal 2005
    • (15) Asplin I et al. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myoinositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II subjects. Proc Natl Acad Sci USA 1993
    • (16) Lamer J, Craig J. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care 1996
    • (17) Jung T S et al. Determination of urinary myo-/chiro-inositol ratios from Korean diabetes patients. Yonsei Med J 2005
    • (18) Ostlund R E Jr et al. D-chiro-inositol metabolism in diabetes mellitus. Proc Natl Acad Sci 1993
    • (19) Kennington A S et al. Low urinary chiro-inositol excretion in non-insulindependent diabetes mellitus. N Engl J Med 1990
    • (20) Bates S H et al. Insulin like effect of pinitol. Br J Pharmacol 2000
    • (21) Baillargeon et al. Altered D-Chiro-Inositol Urinary Clearance in women with PCOS. Diabetes Care 2006
    • (22) Larner et al. D-Chiro-Inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002
    • (23) Benrick A, Maliqueo M, Miao S, Villanueva J A, Feng Y, Ohlsson C, Duleba A J, Stener-Victorin E. Resveratrol is not as effective as physical exercise for improving reproductive and metabolic functions in rats with dihydrotestosterone-induced polycystic ovary syndrome. Evid Based Complement Alternat Med. 2013; 2013:964070.
    • (24) Ruiz-Sanz J L. et altri. Ala16Val SOD2 polymorphism is associated with higher pregnancy rates in in vitro fertilization cycles. Fertil Steril, 2011 April; 95(5):1601-5
    • (25) Fioretti B., Pagano C, Sisani M. et al., Resveratrolo Spring Form. Per aumentare la biodisponibilita. L′integratore nutrizionale 2013, 16(3): 9-14.
    • (26) Stull A J, Wood K V, Thyfault J P, Campbell W W. Effects of acute pinitol supplementation on plasma pinitol concentration, whole body glucose tolerance, and activation of the skeletal muscle insulin receptor in older humans. Horm Metab Res. 2009 May; 41(5):381-6.
    • (27) (Papalou O, Victor V M, Diamanti-Kandarakis E. Oxidative Stress in Polycystic Ovary Syndrome. Curr Pharm Des. 2016; 22(18):2709-22.
    • (28) Grundy S M, Cleeman J I, Daniels S R, Donato K A, Eckel R H, Franklin B A, Gordon D J, Krauss R M, Savage P J, Smith S C Jr, Spertus J A, Costa F; American Heart Association.; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct. 25; 112(17):2735-52. Epub 2005 Sep. 12. Review.”

Claims (25)

1. (canceled)
2. A method for treating a subject, the method comprising:
administering to the subject a pharmaceutical or nutraceutical composition comprising
myo-inositol and D-chiro-inositol and resveratrol coprecipitated with or supported on magnesium hydroxide
in an effective amount to reduce menstrual cycle alterations and/or infertility associated with polycystic ovary syndrome.
3. (canceled)
4. The method according to claim 2, wherein the molar ratio of [myo-inositol] in a range from 0.01 to 100.
5. The method Composition according to claim 2 wherein the pharmaceutical or nutraceutical composition comprises from 24% to 90% by weight based on the total weight of the composition of myo-inositol and D-chiro-inositol and from 1% to 10% by weight based on the total weight of the composition of resveratrol.
6. (canceled)
7. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition comprises myo-inositol and D-chiro-inositol in a molar ratio comprised from 1 to 5.
8. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition further comprises at least one component chosen from the group consisting of lipoic acid, folic acid, vitamin D, and manganese.
9. The method according to 8, wherein the content of folic acid is comprised from 0.001% to 0.1% by weight based on the total weight of the composition.
10. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition prepared in form
of a solid preparation for oral and buccal use selected from powders, granules, capsules, pills, chewing gums, bolus, cachets, tablets, lozenges, and medicinal chocolates.
11. The method according to claim 2, wherein the molar ratio of [myo-inositol]/[D-chiro-inositol] in the in the pharmaceutical or nutraceutical composition is between 1 and 5.
12. The method according to claim 2, wherein the molar ratio of [myo-inositol] [D-chiro-inositol] in the pharmaceutical or nutraceutical composition is less than 2.5.
13. The method according to claim 2, wherein the molar ratio of [myo-inositol] [D-chiro-inositol] in the pharmaceutical or nutraceutical composition is between 0.001 and 07.
14. The method according to claim 2, wherein the molar ratio of [myo-inositol]/[D-chiro-inositol] in the pharmaceutical or nutraceutical composition is 0.4.
15. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition further comprise vitamin D3 from 0.00015 to 0.1% by weight based on the total weight of the composition.
16. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition further comprise manganese from 0.001% to 5% by weight based on the total weight of the composition.
17. The method according to claim 7, wherein the myo-inositol and D-chiro-inositol in the pharmaceutical or nutraceutical composition is in a molar ratio less than 2.5.
18. The method according to claim 7, wherein the myo-inositol and D-chiro-inositol in the pharmaceutical or nutraceutical composition is in a molar ratio between 0.001 and 0.7.
19. The method according to claim 7, wherein the myo-inositol and D-chiro-inositol in the pharmaceutical or nutraceutical composition is in a molar ratio of 0.4.
20. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition is prepared in a form of liquid/semisolid preparation for oral use selected from the group consisting of syrups, elixirs, pastes, juices, decoction, suspensions, emulsions, mucilages, herbal teas, medicinal wines, and potions.
21. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition is in a form for skin applications selected from the group consisting of creams, ointments, gels, emulsions, lotions, linings, medicinal soaps, medicinal shampoos, non-medical shampoos, skin pencils, poultice, gums, oils, oleolites, ointments, dyes, and medicated gauzes.
22. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition is prepared in a form of ear, nasal and mucous membrane preparations selected from the group consisting of collutories, gargles, ear washings, ear cuffs, nasal washings, tampons, oils, oleolites, emulsions, ointments, gels, emulgel, lipogels, tablets, capsules, films, and medicated plasters.
23. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition is prepared in a form of ophthalmic preparations selected from the group consisting of eye drops, ophthalmic inserts and ocular baths.
24. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition is prepared in a form for administration through the lower (anal and vaginal) cavities selected from the group consisting of suppositories, capsules, tablets, enemas, medical irrigation, lavages, foams, tampons, pessary, ovule drugs, foams, gels, pastes, emulsion, creams, ointments, films, suspensions, wraps, plasters, rings, and medicated gauzes.
25. The method according to claim 2, wherein the pharmaceutical or nutraceutical composition is prepared in a form of spray preparation for topical, inhalation, oral, and buccal use.
US17/583,051 2016-04-13 2022-01-24 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto Pending US20220395460A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/583,051 US20220395460A1 (en) 2016-04-13 2022-01-24 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITUA2016A002575A ITUA20162575A1 (en) 2016-04-13 2016-04-13 Pharmaceutical or nutraceutical composition for use in the treatment of polycystic ovary syndrome or diseases or disorders related to it
IT102016000038243 2016-04-13
PCT/IB2017/052151 WO2017179012A1 (en) 2016-04-13 2017-04-13 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto
US201816093295A 2018-10-12 2018-10-12
US17/583,051 US20220395460A1 (en) 2016-04-13 2022-01-24 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US16/093,295 Continuation US11246834B2 (en) 2016-04-13 2017-04-13 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto
PCT/IB2017/052151 Continuation WO2017179012A1 (en) 2016-04-13 2017-04-13 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto

Publications (1)

Publication Number Publication Date
US20220395460A1 true US20220395460A1 (en) 2022-12-15

Family

ID=56555565

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/093,295 Active 2038-04-26 US11246834B2 (en) 2016-04-13 2017-04-13 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto
US17/583,051 Pending US20220395460A1 (en) 2016-04-13 2022-01-24 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/093,295 Active 2038-04-26 US11246834B2 (en) 2016-04-13 2017-04-13 Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto

Country Status (7)

Country Link
US (2) US11246834B2 (en)
EP (1) EP3452012B1 (en)
ES (1) ES2890050T3 (en)
HU (1) HUE055882T2 (en)
IT (1) ITUA20162575A1 (en)
PL (1) PL3452012T3 (en)
WO (1) WO2017179012A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20162575A1 (en) 2016-04-13 2017-10-13 S&R Farm S P A Pharmaceutical or nutraceutical composition for use in the treatment of polycystic ovary syndrome or diseases or disorders related to it
US11484540B2 (en) 2017-11-23 2022-11-01 Biosearch. S.A. Method for increasing embryo implantation rate in a female subject suffering polycystic ovary syndrome
CN111989093A (en) * 2018-04-16 2020-11-24 S&R制药股份有限公司 A mixture of resveratrol loaded on metal hydroxide and non-loaded pure resveratrol for treating female fertility
IT201800011155A1 (en) * 2018-12-17 2020-06-17 S&R Farm S P A use of a blend of berberine and resveratrol for the control of dyslipidemias
EP4000626A1 (en) * 2020-11-16 2022-05-25 concrete flowers GmbH Pharmaceutical preparation
WO2024127352A1 (en) * 2022-12-15 2024-06-20 Prolabin & Tefarm S.R.L. Formulation comprising vanilloid polyphenols supported on lamellar solids to reduce plasma cgrp levels and its applications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040395A1 (en) 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti COMPOSITION INCLUDING STATINES AND FATTY ACIDS OMEGA 3.
US20100129467A9 (en) 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
US8383165B1 (en) 2009-08-31 2013-02-26 Fairhaven Health, Llc Composition and method for fertility therapy using nutritional supplements
IT1404171B1 (en) * 2011-02-10 2013-11-15 Paladin Pharma S P A COMPOSITION FOR USE IN THE TREATMENT OF PROBLEMS / DISORDERS OF THE MENOPAUSE AND IN THE TREATMENT OF THE GENERAL AGING OF THE ORGANISM
US20130224281A1 (en) 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
ITFI20110252A1 (en) * 2011-11-22 2013-05-23 Lo Li Pharma Srl PHARMACEUTICAL COMPOSITION INCLUDING MYO-INOSITOL AND D-CHIRO-INOSITOL.
ITPG20120030A1 (en) 2012-06-27 2013-12-29 Bernard Fioretti HYBRID INORGANIC RESVERATROL
ITRM20130655A1 (en) * 2013-11-26 2015-05-27 Dicofarm Spa PRODUCT BASED ON AN ASSOCIATION OF GLUCOMANNAN AND INOSITLE
IN2014MU01312A (en) * 2014-04-09 2015-10-16 Olive Healthcare
ITUB20153066A1 (en) * 2015-08-11 2017-02-11 Graal S R L FOOD AND / OR NUTRACEUTICAL COMPOSITION CONTAINING PEA
ITUA20162575A1 (en) 2016-04-13 2017-10-13 S&R Farm S P A Pharmaceutical or nutraceutical composition for use in the treatment of polycystic ovary syndrome or diseases or disorders related to it
US10092545B2 (en) 2016-04-30 2018-10-09 Fairhaven Health, Llc Nutritional supplements for improving female fertility
CN111989093A (en) 2018-04-16 2020-11-24 S&R制药股份有限公司 A mixture of resveratrol loaded on metal hydroxide and non-loaded pure resveratrol for treating female fertility

Also Published As

Publication number Publication date
US11246834B2 (en) 2022-02-15
ITUA20162575A1 (en) 2017-10-13
HUE055882T2 (en) 2021-12-28
PL3452012T3 (en) 2022-01-24
EP3452012A1 (en) 2019-03-13
EP3452012B1 (en) 2021-06-23
ES2890050T3 (en) 2022-01-17
US20190125675A1 (en) 2019-05-02
WO2017179012A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
US20220395460A1 (en) Nutraceutical or pharmaceutical composition for use in the treatment of polycystic ovary syndrome or of diseases or disorders related thereto
JP5785546B2 (en) Method for preventing or treating cerebral ischemia
AU2022291541A1 (en) Sublingual or buccal administration of dim for treatment of skin diseases
CN117323323A (en) Activation of AMPK by Phoebe cheilis component
US20070218126A1 (en) Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis
EP3843744A1 (en) Folate preparations
KR102605627B1 (en) Leucine derivatives, composition comprising the same, and uses thereof
CN109381473B (en) Application of baicalin in preparation of medicine for preventing gestational diabetes mellitus fetal neural tube malformation
WO2016131321A1 (en) Use of nadph in preparing medicines for treatment of cardiovascular and cerebrovascular diseases
JP2021504360A (en) How to Increase Embryo Implantation Rate in Female Patients with Polycystic Ovary Syndrome
CN118019535A (en) Methods of treating sickle cell disease using quercetin-containing compositions
WO2017036971A1 (en) Prophylaxis of hypertension and cardiovascular diseases
RU2493841C1 (en) Synergetic preparation for treating cardiovascular diseases, diabetes mellitus and hepatobiliary diseases
EP4205734A1 (en) Application of ?-asarone in preparation of medicine for preventing or treating hemorrhagic stroke
US20230277491A1 (en) Pharmaceutical combination comprising glycolic acid and l-alanine
EP4122484A1 (en) Use of cyclo-hispro (chp) for lowering blood pressure
CN110051671B (en) Application of purslane amide E in preparation of medicine for treating ischemic heart disease
WO2013083025A1 (en) Composition used in manufacturing of medicaments for treatment of cerebrovascular diseases
KR et al. Clinical Evaluation of an Ayurvedic Preparation “Sangfer” for the Treatment of Anemia in Pregnant Women: An Open-labeled Clinical Study
CN115120597A (en) Novel Nrf2 activator and application thereof
CN117357506A (en) Application of salvianolic acid A in treatment of calcified aortic valve diseases
CN104069119B (en) A kind of application of helicidum and preparation
CN117017936A (en) Glycoside compound microemulsion soft capsule and preparation method thereof
KR20230080579A (en) Pharmaceutical composition for treating or preventing cutaneous radiation syndromes comprising zileuton as an active ingredient
CN117695324A (en) New use of eucommia male flower pollen and/or eucommia male flower and composition containing the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: S&R FARMACEUTICI S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FIORETTI, BERNARD;LEONARDI, LUCIO;REEL/FRAME:060788/0119

Effective date: 20190801

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION